Haploidentical and Matched Sibling Transplantation for Acute Myeloid Leukemia: A Hospital-Based Study.
Juan C BaenaMaria C RosalesMayra EstacioAlejandra HidalgoElizabeth ArrietaFrancisco J JaramilloEliana ManziLuis Gabriel Parra-LaraJoaquin D RosalesPublished in: Journal of hematology (2023)
These results underline that MSD remains the first donor choice for AML patients in CR1 when available. HRDs are still our next option among alternative donors. It is necessary to find strategies that have a positive impact on those outcomes that markedly affect the quality of allogeneic PBSCT and the prognosis of patients. Comparative, randomized, prospective studies with longer follow-up of haploidentical allogeneic PBSCT with other donor types are required to definitely establish its role among alternative donors.
Keyphrases
- stem cell transplantation
- acute myeloid leukemia
- end stage renal disease
- bone marrow
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- peripheral blood
- stem cells
- metabolic syndrome
- randomized controlled trial
- open label
- double blind
- patient reported outcomes
- skeletal muscle
- mesenchymal stem cells
- cell therapy
- cord blood
- phase ii